Eczema sufferers get new hope: pill shows promise after biologic failure
NCT ID NCT07550452
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether switching to a pill called ivarmacitinib can help people with moderate-to-severe eczema (atopic dermatitis) who did not get enough relief from standard injectable drugs. About 300 adults will take the pill for 16 weeks. The goal is to see if their skin clears and itching improves.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged between 18 and 75 years. * Patients diagnosed with moderate-to-severe atopic dermatitis and treated with IL-4Rα inhibitors according to standard regimens for a minimum of 12 weeks. * Meeting any of the following disease activity criteria: EASI ≥16, WI-NRS ≥4. Exclusion Criteria: * Treatment with other JAK inhibitors, including topical formulations, within one week before enrollment. * Subjects with clinically significant diseases of the heart, liver, kidney, or other major organ systems. * Subject has any of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary: a. Absolute lymphocyte count of \<0.50 x 10\^9 /L (\<500/mm3);b. Absolute Neutrophil Count (ANC) of \<1 X 10\^9/L (\<1000/mm3);c. Hemoglobin level \< 80 g/L. * Subject with a prior history of thromboembolic events, including deep vein thromboses (DVT), pulmonary embolism, cerebrovascular accidents and those with known inherited conditions that predispose to hypercoagulability. * Presence of an active severe acute or chronic bacterial, fungal, or viral infection requiring systemic therapy. * Subjects with active tuberculosis or known active hepatitis B and/or hepatitis C infection. * Subject has any malignancies or has a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ. * Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.